Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.60 |
| ▸ | MME | P08473 | 8/20 | 0.60 |
| ▸ | XIAP | P98170 | 5/20 | 0.57 |
| ▸ | BCL2L11 | O43521 | 3/20 | 0.56 |
| ▸ | BCL2 | P10415 | 3/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329177 | 1.00 | ACE (0.60) | ACEMMEXIAPBCL2L11BCL2 | |
| SCHEMBL2359073 | 0.80 | MME (0.58) | ACEMMEXIAP | |
| SCHEMBL29494164 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL7441045 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL6440328 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL7444580 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL7444571 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL6440330 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL7343245 | 0.75 | ACE (1.00) | ACEMME | |
| SCHEMBL7368989 | 0.75 | ACE (1.00) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | ACE 3425/4885MME 3989/4885XIAP 1/4885 |
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | ACE 3421/4885MME 3990/4885XIAP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.